Neurocrine Biosciences
NBIX
NBIX
406 hedge funds and large institutions have $8.86B invested in Neurocrine Biosciences in 2021 Q2 according to their latest regulatory filings, with 48 funds opening new positions, 167 increasing their positions, 130 reducing their positions, and 54 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
406
Holders Change
-11
Holders Change %
-2.64%
% of All Funds
7.09%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
48
Increased
167
Reduced
130
Closed
54
Calls
$83.8M
Puts
$54.6M
Net Calls
+$29.2M
Net Calls Change
+$12M
Top Buyers
| 1 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$40.6M |
| 2 |
HM
HealthCor Management
New York
|
+$38M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$37.5M |
| 4 |
Morgan Stanley
New York
|
+$23.3M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$19.8M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$280M |
| 2 |
BlackRock
New York
|
-$82.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$72.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$45.5M |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$44.4M |
